Drug treatment may benefit only select group of patients with glioblastoma
the ONA take:
Clinicians testing dasatinib, approved for several blood cancers, were hoping to find that it would slow the growth of glioblastomas. They found that the drug does inhibit proteins that promote tumor growth; however, it also inhibits proteins that protect against cancer, a finding that negates any benefit of using the drug for patients with glioblastoma.
Findings from the researchers at Mayo Clinic, who conducted one of the clinical trials, suggest that pretesting glioblastoma biopsies may help identify those patients who will benefit from treatment with dasatinib. The drug is a general Src-family kinase (SFK) inhibitor.
The researchers teased apart the effect on individual Src family members (Src, Fyn, Yes, and Lyn). They found that dasatinib inhibited Src, Fyn, and Yes, which reduced growth and migration. It also inhibited Lyn, which protects against cancer growth.
The researchers also found that tumors express all members of the Src family differently, and expression of Yes and Lyn differed among tumors.
Although further testing is needed, the findings suggest that some patients may derive benefit from treatment with dasatinib, in particular those whose tumors express Yes, but not Lyn.
Clinicians testing dasatinib, approved for several blood cancers, were hoping to find that it would slow the growth of glioblastomas.
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- LIVESTRONG Exercise Program Improves QoL in Cancer Survivors
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Costs, Complications Higher for Women Who Undergo Second Surgery After BCS
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression
- Assessment of Stromal Features in DCIS Requires Robustness
- Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: the evidence to date
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|